Neurology, Vol 45, Issue 6 1115-1121, Copyright © 1995 by American Academy of Neurology

ARTICLES

Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects

PJ Dyck, WJ Litchy, KA Lehman, JL Hokanson, PA Low and PC O'Brien
Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.

We determined the normal limits for various neuropathic tests in healthy subjects. The study, the Rochester Diabetic Neuropathy Study (RDNS), is noteworthy because of its size (more than 400 subjects), random selection of subjects, and selection of at least 15 men and 15 women without neuropathy, neurologic disease, or diseases predisposing to neuropathy from each hemidecade between 18 and 74 years of age from the population of a defined region (Rochester, MN). Subjects were classified into those with (nonhealthy subjects, RDNS-NS) and without (healthy subjects, RDNS-HS) neuropathy, neurologic or psychiatric disease, or diseases known to predispose to neuropathy. The study provides normal limits for tests used in the RDNS but it has broader uses as well. We found that (1) less than 10% of subjects in the third decade, approximately 20% in the fourth decade, and approximately 30% in the fifth or older decades were placed into the RDNS-NS category; (2) healthy subjects (RDNS-HS) retain their ability to walk on toes and heels regardless of age, excessive weight, or lack of physical fitness, but not their ability to arise from a kneeled position--lost in more than 5% of persons 60 years and older; (3) the frequency of decreased or absent ankle reflexes exceeds 5% in healthy subjects older than 50 years--limiting their value as a sign of diabetic polyneuropathy and necessitating a grading change with age in the neuropathy impairment score.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				M. E. Shy, L. Chen, E. R. Swan, R. Taube, K. M. Krajewski, D. Herrmann, R. A. Lewis, and M. P. McDermott Neuropathy progression in Charcot-Marie-Tooth disease type 1A Neurology, January 29, 2008; 70(5): 378 - 383. [Abstract] [Full Text] [PDF]

				P. J. Dyck, J. E. Norell, H. Tritschler, K. Schuette, R. Samigullin, D. Ziegler, E. J. Bastyr III, W. J. Litchy, and P. C. O'Brien Challenges in Design of Multicenter Trials: End points assessed longitudinally for change and monotonicity Diabetes Care, October 1, 2007; 30(10): 2619 - 2625. [Abstract] [Full Text] [PDF]

				C. M. Casellini, P. M. Barlow, A. L. Rice, M. Casey, K. Simmons, G. Pittenger, E. J. Bastyr III, A. M. Wolka, and A. I. Vinik A 6-Month, Randomized, Double-Masked, Placebo-Controlled Study Evaluating the Effects of the Protein Kinase C-{beta} Inhibitor Ruboxistaurin on Skin Microvascular Blood Flow and Other Measures of Diabetic Peripheral Neuropathy Diabetes Care, April 1, 2007; 30(4): 896 - 902. [Abstract] [Full Text] [PDF]

				E. R. Swan, D. R. Fuerst, and M. E. Shy Women and men are equally disabled by Charcot-Marie-Tooth disease type 1A Neurology, March 13, 2007; 68(11): 873 - 873. [Full Text] [PDF]

				L. SIBAL, H. N. LAW, J. GEBBIE, and P. HOME Cardiovascular Risk Factors Predicting the Development of Distal Symmetrical Polyneuropathy in People with Type 1 Diabetes: A 9-Year Follow-up Study Ann. N.Y. Acad. Sci., November 1, 2006; 1084(1): 304 - 318. [Abstract] [Full Text] [PDF]

				P. J. Dyck, J. L. Davies, V. M. Clark, W. J. Litchy, P. J. B. Dyck, C. J. Klein, R. A. Rizza, J. M. Pach, R. Klein, T. S. Larson, et al. Modeling Chronic Glycemic Exposure Variables as Correlates and Predictors of Microvascular Complications of Diabetes Diabetes Care, October 1, 2006; 29(10): 2282 - 2288. [Abstract] [Full Text] [PDF]

				D H Kilfoyle, P J Dyck, Y Wu, W J Litchy, D M Klein, P J B Dyck, N Kumar, J M Cunningham, and C J Klein Myelin protein zero mutation His39Pro: hereditary motor and sensory neuropathy with variable onset, hearing loss, restless legs and multiple sclerosis. J. Neurol. Neurosurg. Psychiatry, August 1, 2006; 77(8): 963 - 966. [Abstract] [Full Text] [PDF]

				C. Hoffman-Snyder, B. E. Smith, M. A. Ross, J. Hernandez, and E. P. Bosch Value of the Oral Glucose Tolerance Test in the Evaluation of Chronic Idiopathic Axonal Polyneuropathy Arch Neurol, August 1, 2006; 63(8): 1075 - 1079. [Abstract] [Full Text] [PDF]

				D. N. Herrmann, M. P. McDermott, J. E. Sowden, D. Henderson, S. Messing, K. Cruttenden, and G. Schifitto Is skin biopsy a predictor of transition to symptomatic HIV neuropathy?: A longitudinal study Neurology, March 28, 2006; 66(6): 857 - 861. [Abstract] [Full Text] [PDF]

				Z. Sahenk, H. N. Nagaraja, B. S. McCracken, W. M. King, M. L. Freimer, J. M. Cedarbaum, and J. R. Mendell NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients Neurology, September 13, 2005; 65(5): 681 - 689. [Abstract] [Full Text] [PDF]

				P. J. Dyck, P. C. O'Brien, W. J. Litchy, C. M. Harper, C. J. Klein, and P. J. B. Dyck Monotonicity of Nerve Tests in Diabetes: Subclinical nerve dysfunction precedes diagnosis of polyneuropathy Diabetes Care, September 1, 2005; 28(9): 2192 - 2200. [Abstract] [Full Text] [PDF]

				H. Kelsall, R. Macdonell, M. Sim, A. Forbes, D. McKenzie, D. Glass, J. Ikin, and P. Ittak Neurological status of Australian veterans of the 1991 Gulf War and the effect of medical and chemical exposures Int. J. Epidemiol., August 1, 2005; 34(4): 810 - 819. [Abstract] [Full Text] [PDF]

				J. K. Baillie, I. Power, S. Tesfaye, D. Selvarajah, I. Gilron, and D. F. Weaver Morphine, Gabapentin, or Their Combination for Neuropathic Pain N. Engl. J. Med., June 23, 2005; 352(25): 2650 - 2651. [Full Text] [PDF]

				M. E. Shy, J. Blake, K. Krajewski, D. R. Fuerst, M. Laura, A. F. Hahn, J. Li, R. A. Lewis, and M. Reilly Reliability and validity of the CMT neuropathy score as a measure of disability Neurology, April 12, 2005; 64(7): 1209 - 1214. [Abstract] [Full Text] [PDF]

				G A Suarez, V M Clark, J E Norell, T E Kottke, M J Callahan, P C O'Brien, P A Low, and P J Dyck Sudden cardiac death in diabetes mellitus: risk factors in the Rochester diabetic neuropathy study J. Neurol. Neurosurg. Psychiatry, February 1, 2005; 76(2): 240 - 245. [Abstract] [Full Text] [PDF]

				Z. Zhou, A. Hoke, D. R. Cornblath, J. W. Griffin, and M. Polydefkis APOE {epsilon}4 is not a susceptibility gene in idiopathic or diabetic sensory neuropathy Neurology, January 11, 2005; 64(1): 139 - 141. [Abstract] [Full Text] [PDF]

				P. A. Low, L. M. Benrud-Larson, D. M. Sletten, T. L. Opfer-Gehrking, S. D. Weigand, P. C. O'Brien, G. A. Suarez, and P. J. Dyck Autonomic Symptoms and Diabetic Neuropathy: A population-based study Diabetes Care, December 1, 2004; 27(12): 2942 - 2947. [Abstract] [Full Text] [PDF]

				N Sathiakumar, E Delzell, P A MacLennan, M Anne, N L Rosenberg, H Cheng, and S L Myers A cross-sectional study of triallate exposure and neurological health among workers at a pesticide manufacturing and formulating facility Occup. Environ. Med., November 1, 2004; 61(11): 936 - 944. [Abstract] [Full Text] [PDF]

				H. H. Kramer, R. Rolke, A. Bickel, and F. Birklein Thermal Thresholds Predict Painfulness of Diabetic Neuropathies Diabetes Care, October 1, 2004; 27(10): 2386 - 2391. [Abstract] [Full Text] [PDF]

				J W Albers, D H Garabrant, S J Schweitzer, R P Garrison, R J Richardson, and S Berent The effects of occupational exposure to chlorpyrifos on the peripheral nervous system: a prospective cohort study Occup. Environ. Med., March 1, 2004; 61(3): 201 - 211. [Abstract] [Full Text] [PDF]

				H. H. Kramer, M. Schmelz, F. Birklein, and A. Bickel Electrically Stimulated Axon Reflexes Are Diminished in Diabetic Small Fiber Neuropathies Diabetes, March 1, 2004; 53(3): 769 - 774. [Abstract] [Full Text] [PDF]

				M.E. Shy, E.M. Frohman, Y.T. So, J.C. Arezzo, D.R. Cornblath, M.J. Giuliani, J.C. Kincaid, J.L. Ochoa, G.J. Parry, and L.H. Weimer Quantitative sensory testing: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology, March 25, 2003; 60(6): 898 - 904. [Abstract] [Full Text] [PDF]

				C.J. Sumner, S. Sheth, J.W. Griffin, D.R. Cornblath, and M. Polydefkis The spectrum of neuropathy in diabetes and impaired glucose tolerance Neurology, January 14, 2003; 60(1): 108 - 111. [Abstract] [Full Text] [PDF]

				K. R. Sharma, J. Cross, D. R. Ayyar, A. Martinez-Arizala, and W. G. Bradley Diabetic Demyelinating Polyneuropathy Responsive to Intravenous Immunoglobulin Therapy Arch Neurol, May 1, 2002; 59(5): 751 - 757. [Abstract] [Full Text] [PDF]

				K. R. Sharma, J. Cross, O. Farronay, D. R. Ayyar, R. T. Shebert, and W. G. Bradley Demyelinating Neuropathy in Diabetes Mellitus Arch Neurol, May 1, 2002; 59(5): 758 - 765. [Abstract] [Full Text] [PDF]

				A. F. J. E. Vrancken, H. Franssen, J. H. J. Wokke, L. L. Teunissen, and N. C. Notermans Chronic Idiopathic Axonal Polyneuropathy and Successful Aging of the Peripheral Nervous System in Elderly People Arch Neurol, April 1, 2002; 59(4): 533 - 540. [Abstract] [Full Text] [PDF]

				D. H. Weinberg, D. Simovic, J. Isner, and A. H. Ropper Chronic ischemic monomelic neuropathy from critical limb ischemia Neurology, September 25, 2001; 57(6): 1008 - 1012. [Abstract] [Full Text] [PDF]

				P. J. B. Dyck, J. E. Norell, and P. J. Dyck Non-diabetic lumbosacral radiculoplexus neuropathy: Natural history, outcome and comparison with the diabetic variety Brain, June 1, 2001; 124(6): 1197 - 1207. [Abstract] [Full Text] [PDF]

				S. Matzke and M. Lepantalo Claudication does not always precede critical leg ischemia Vascular Medicine, May 1, 2001; 6(2): 77 - 80. [Abstract] [PDF]

				H. E. Resnick, A. I. Vinik, H. K. Heimovitz, F. L. Brancati, and J. M. Guralnik Age 85+ Years Accelerates Large-Fiber Peripheral Nerve Dysfunction and Diabetes Contributes Even in the Oldest-Old: The Women's Health and Aging Study J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2001; 56(1): 25M - 31. [Abstract] [Full Text]

				S. C. Apfel, S. Schwartz, B. T. Adornato, R. Freeman, V. Biton, M. Rendell, A. Vinik, M. Giuliani, J. C. Stevens, R. Barbano, et al. Efficacy and Safety of Recombinant Human Nerve Growth Factor in Patients With Diabetic Polyneuropathy: A Randomized Controlled Trial JAMA, November 1, 2000; 284(17): 2215 - 2221. [Abstract] [Full Text] [PDF]

				M. Polydefkis, R. P. Allen, P. Hauer, C. J. Earley, J. W. Griffin, and J. C. McArthur Subclinical sensory neuropathy in late-onset restless legs syndrome Neurology, October 24, 2000; 55(8): 1115 - 1121. [Abstract] [Full Text] [PDF]

				P. J. B. Dyck, J. E. Norell, and P. J. Dyck Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy Neurology, December 1, 1999; 53(9): 2113 - 2113. [Abstract] [Full Text]

				M. I. Periquet, V. Novak, M. P. Collins, H. N. Nagaraja, S. Erdem, S. M. Nash, M. L. Freimer, Z. Sahenk, J. T. Kissel, and J. R. Mendell Painful sensory neuropathy: Prospective evaluation using skin biopsy Neurology, November 1, 1999; 53(8): 1641 - 1641. [Abstract] [Full Text] [PDF]

				J. E. Riggs, S. C. Apfel, W. J. Litchy, J. A. Kessler, C. Sanders, B. T. Adornato, and C. A. Rask Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy Neurology, April 1, 1999; 52(7): 1517 - 1517. [Full Text]

				M. Backonja, A. Beydoun, K. R. Edwards, S. L. Schwartz, V. Fonseca, M. Hes, L. LaMoreaux, E. Garofalo, and for the Gabapentin Diabetic Neuropathy Study Group Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients With Diabetes Mellitus: A Randomized Controlled Trial JAMA, December 2, 1998; 280(21): 1831 - 1836. [Abstract] [Full Text] [PDF]

				C. M. HARPER and A. G. ENGEL Safety and Efficacy of Quinidine Sulfate in Slow-Channel Congenital Myasthenic Syndrome Ann. N.Y. Acad. Sci., May 13, 1998; 841(1): 203 - 206. [Full Text]